| Bioactivity | Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. |
| Name | Canlitinib |
| CAS | 2222730-78-9 |
| Formula | C33H31F2N3O7 |
| Molar Mass | 619.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang, Zhiqiang, et al. Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof. WO2017-CN104518 |
Canlitinib
CAS: 2222730-78-9 F: C33H31F2N3O7 W: 619.61
Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for c
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.